Friedreich Ataxia Caregiver-Reported Health Index: Development of a Novel, Disease-Specific Caregiver-Reported Outcome Measure.

IF 2.3 Q3 CLINICAL NEUROLOGY Neurology. Clinical practice Pub Date : 2024-06-01 Epub Date: 2024-05-10 DOI:10.1212/CPJ.0000000000200300
Jamison Seabury, Anika Varma, Jennifer Weinstein, Spencer J Rosero, Charlotte Engebrecht, Shaweta Khosa, Christine Zizzi, Ellen S Wagner, Danae Alexandrou, Brittany L Cohen, Nuran Dilek, John M Heatwole, David R Lynch, Courtney C Park, McKenzie Wells, S H Subramony, Chad R Heatwole
{"title":"Friedreich Ataxia Caregiver-Reported Health Index: Development of a Novel, Disease-Specific Caregiver-Reported Outcome Measure.","authors":"Jamison Seabury, Anika Varma, Jennifer Weinstein, Spencer J Rosero, Charlotte Engebrecht, Shaweta Khosa, Christine Zizzi, Ellen S Wagner, Danae Alexandrou, Brittany L Cohen, Nuran Dilek, John M Heatwole, David R Lynch, Courtney C Park, McKenzie Wells, S H Subramony, Chad R Heatwole","doi":"10.1212/CPJ.0000000000200300","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>The Friedreich ataxia (FRDA) scientific community needs access to patient-centered outcome measures that satisfy regulatory guidelines and are capable of tracking clinically meaningful changes in FRDA disease burden. The objective of this research was to develop a novel, disease-specific caregiver-reported outcome measure for use in FRDA research and clinical care.</p><p><strong>Methods: </strong>In prior work, we conducted qualitative interviews and a cross-sectional study of FRDA caregivers and patients to determine the symptoms of greatest importance to individuals with FRDA. We designed the Friedreich Ataxia Caregiver-Reported Health Index (FACR-HI) to serially measure the symptoms of greatest importance to patients and utilized factor analysis, beta testing, reliability testing, and cross-sectional subgroup analysis to further evaluate and optimize this disease-specific outcome measure.</p><p><strong>Results: </strong>The FACR-HI was designed to measure total disease burden and disease burden in 18 symptomatic domains. The FACR-HI total score demonstrated high internal consistency (Cronbach's α = 0.98) and test-retest reliability (intraclass correlation coefficient = 0.96). Beta interview participants found the FACR-HI to be highly relevant, comprehensive, and easy to use. FACR-HI total and subscale scores were associated with functional staging for ataxia scores and speech impairment.</p><p><strong>Discussion: </strong>Initial evaluation of the FACR-HI supports its content validity, test-retest reliability, and construct validity as a caregiver-reported outcome measure for assessing how pediatric individuals with FRDA feel and function. The FACR-HI provides a potential mechanism to quantify changes in multifactorial FRDA disease burden during future clinical trials.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11092940/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology. Clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/CPJ.0000000000200300","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: The Friedreich ataxia (FRDA) scientific community needs access to patient-centered outcome measures that satisfy regulatory guidelines and are capable of tracking clinically meaningful changes in FRDA disease burden. The objective of this research was to develop a novel, disease-specific caregiver-reported outcome measure for use in FRDA research and clinical care.

Methods: In prior work, we conducted qualitative interviews and a cross-sectional study of FRDA caregivers and patients to determine the symptoms of greatest importance to individuals with FRDA. We designed the Friedreich Ataxia Caregiver-Reported Health Index (FACR-HI) to serially measure the symptoms of greatest importance to patients and utilized factor analysis, beta testing, reliability testing, and cross-sectional subgroup analysis to further evaluate and optimize this disease-specific outcome measure.

Results: The FACR-HI was designed to measure total disease burden and disease burden in 18 symptomatic domains. The FACR-HI total score demonstrated high internal consistency (Cronbach's α = 0.98) and test-retest reliability (intraclass correlation coefficient = 0.96). Beta interview participants found the FACR-HI to be highly relevant, comprehensive, and easy to use. FACR-HI total and subscale scores were associated with functional staging for ataxia scores and speech impairment.

Discussion: Initial evaluation of the FACR-HI supports its content validity, test-retest reliability, and construct validity as a caregiver-reported outcome measure for assessing how pediatric individuals with FRDA feel and function. The FACR-HI provides a potential mechanism to quantify changes in multifactorial FRDA disease burden during future clinical trials.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
弗里德里希共济失调症护理者健康指数(Friedreich Ataxia Caregiver-Reported Health Index):开发一种新的、针对特定疾病的护理人员报告结果测量方法。
背景和目标:弗里德里希共济失调(FRDA)科学界需要获得以患者为中心的结果测量方法,这些方法既要符合法规指南,又要能够追踪FRDA疾病负担中具有临床意义的变化。本研究的目的是开发一种新型的、疾病特异性的护理人员报告结果测量方法,用于弗里德里希共济失调症的研究和临床护理:在之前的工作中,我们对 FRDA 护理人员和患者进行了定性访谈和横断面研究,以确定对 FRDA 患者最重要的症状。我们设计了弗里德里希共济失调护理者健康指数(FACR-HI)来连续测量对患者最重要的症状,并利用因子分析、β测试、可靠性测试和横断面亚组分析来进一步评估和优化这一疾病特异性结果测量:结果:设计 FACR-HI 的目的是测量疾病总负担和 18 个症状领域的疾病负担。FACR-HI 总分显示出较高的内部一致性(Cronbach's α = 0.98)和测试-再测试可靠性(类内相关系数 = 0.96)。Beta 访谈参与者认为 FACR-HI 高度相关、全面且易于使用。FACR-HI 总分和分量表得分与共济失调得分和语言障碍的功能分期相关:讨论:FACR-HI 的初步评估支持其内容效度、测试再测可靠性和构造效度,可作为一种由护理人员报告的结果测量方法,用于评估患有 FRDA 的儿科患者的感觉和功能。在未来的临床试验中,FACR-HI 为量化多因素 FRDA 疾病负担的变化提供了一种潜在机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neurology. Clinical practice
Neurology. Clinical practice CLINICAL NEUROLOGY-
CiteScore
4.00
自引率
0.00%
发文量
77
期刊介绍: Neurology® Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. The journal publishes original articles in all areas of neurogenetics including rare and common genetic variations, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease genes, and genetic variations with a putative link to diseases. Articles include studies reporting on genetic disease risk, pharmacogenomics, and results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology® Genetics, but studies using model systems for treatment trials, including well-powered studies reporting negative results, are welcome.
期刊最新文献
An Interprofessional Team for Disease-Modifying Therapy in Alzheimer Disease Implementation. Virtual Compared With In-Person Neurologic Examination Study. A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders: A Consensus Statement. Access to Care and Health-Related Quality of Life in Multiple Sclerosis. Antiseizure Medication Withdrawal, Risk of Epilepsy, and Longterm EEG Trends in Acute Symptomatic Seizures or Epileptic EEG Patterns.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1